Sucu Bilgesu Onur, Koc Elif Beyza, Savlug Ipek Ozgecan, Mirat Afranur, Almas Furkan, Guzel Melike Aybala, Dogan Berna, Uludag Damla, Karakas Nihal, Durdagi Serdar, Guzel Mustafa
Istanbul Medipol University, Research Institute for Health Sciences and Technologies SABITA, Center of Drug Discovery and Development, Istanbul, Turkey; Istanbul Medipol University, Vocational School of Health Services, Department of Medical Services and Techniques, Istanbul, Turkey.
Istanbul Medipol University, Research Institute for Health Sciences and Technologies SABITA, Center of Drug Discovery and Development, Istanbul, Turkey; Istanbul Medipol University, Health Sciences Institute, Department of Molecular Medicine and Biotechnology, Istanbul, Turkey.
J Mol Graph Model. 2022 Jun;113:108160. doi: 10.1016/j.jmgm.2022.108160. Epub 2022 Feb 20.
Glioblastoma Multiforme (GBM) is the most aggressive brain tumor and classified as one of the deadliest cancers. The current treatment plans for GBM remains to be ineffective because of its rapid progress and inability of the drugs used to cross the blood-brain barrier (BBB). Thus, developing more effective and potent medicines for GBM are needed. There have been several reports demonstrating that CAPE presents reasonably good anti-cancer activity in certain cancer cell lines and can penetrate the blood-brain barrier. Accordingly, in this study we synthesized several novel CAPE analogs with the addition of more druggable handles and solubilizing entities and subsequently evaluated their in vitro therapeutic efficacies in GBM cell lines (T98G and LN229). The most potent compound was then examined extensively and results showed that the 50 μM novel CAPE analog (compound 10) significantly decreases the viability of both T98G and LN229 GBM cells as compared to CAPE itself. Moreover, the compound 10 was not cytotoxic to healthy human cells (fibroblast-like mesenchymal stem cells) at the same concentration. Apoptotic (32.8%, and 44.6%) cell populations were detected in the compound 10 treated groups for LN229 and T98G, respectively. As an indication of apotosis, significantly increased PARP cleavage was detected in compound 10 versus CAPE treated LN229. In addition, we conducted molecular docking and molecular dynamics (MD) simulations studies on certain targets playing roles on GBM disease pathway such as NF-κB, EGFR, TNF-α, ERK2, PAPR1, hCA IX and hCA XII. Our findings demonstrated that designed CAPE analogs have anti-cancer activity on GBM cells and in silico studies also demonstrate the inhibitory ability of suggested compounds via interactions with critical residues in binding pockets of studied targets. Here, we suggest the novel CAPE analog to study further against GBM. Therefore, identification of the compound related molecular signature may provide more to understand the mechanism of action.
多形性胶质母细胞瘤(GBM)是最具侵袭性的脑肿瘤,被归类为最致命的癌症之一。由于其进展迅速且所用药物无法穿过血脑屏障(BBB),目前GBM的治疗方案仍然无效。因此,需要开发更有效、更有潜力的GBM药物。有几份报告表明,咖啡酸苯乙酯(CAPE)在某些癌细胞系中具有相当好的抗癌活性,并且可以穿透血脑屏障。因此,在本研究中,我们合成了几种新型的CAPE类似物,添加了更多可成药基团和增溶基团,随后评估了它们在GBM细胞系(T98G和LN229)中的体外治疗效果。然后对最有效的化合物进行了广泛研究,结果表明,与CAPE本身相比,50μM的新型CAPE类似物(化合物10)显著降低了T98G和LN229 GBM细胞的活力。此外,化合物10在相同浓度下对健康人类细胞(成纤维样间充质干细胞)没有细胞毒性。在化合物10处理的LN229和T98G组中分别检测到凋亡细胞群体(32.8%和44.6%)。作为凋亡的指标,在化合物10处理的LN229细胞中检测到PARP裂解显著增加,而CAPE处理的LN229细胞中未检测到。此外,我们对在GBM疾病途径中起作用的某些靶点,如NF-κB、表皮生长因子受体(EGFR)、肿瘤坏死因子-α(TNF-α)、细胞外信号调节激酶2(ERK2)、聚(ADP-核糖)聚合酶1(PAPR1)、人碳酸酐酶IX(hCA IX)和人碳酸酐酶XII(hCA XII)进行了分子对接和分子动力学(MD)模拟研究。我们的研究结果表明,设计的CAPE类似物对GBM细胞具有抗癌活性,计算机模拟研究也证明了所建议化合物通过与研究靶点结合口袋中的关键残基相互作用的抑制能力。在此,我们建议对新型CAPE类似物针对GBM进行进一步研究。因此,鉴定与化合物相关的分子特征可能有助于更深入地了解其作用机制。